NCT06122285View on ClinicalTrials.gov

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

December 31, 2025

Conditions
Hepatitis D
Interventions
DRUG

Bulevirtide

dose of 2 mg/day subcutaneously

Trial Locations (1)

20122

RECRUITING

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy., Milan

All Listed Sponsors
lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER